News Search Results
Sep 29, 2026, 03:45 ET 2026 IMS Oral Presentation: Innovent Announces Updated Phase 1 Clinical Data of Trispecific Antibody IBI3003 (GPRC5D/BCMA/CD3) in Patients with Relapsed or Refractory Multiple Myeloma
IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA, and CD3, in patients with relapsed or refractory multiple myeloma (R/R MM) in an oral presentation at the 23rd International Myeloma Society (IMS) Annual Meeting 2026. Based on the results of the Phase 1 dose optimization study, the recommended Phase
More news about: Innovent Biologics
Sep 26, 2026, 23:16 ET 2026 IMS | IASO Bio Presented FUCASO China Real-World Data
autoleucel injection, Eque-cel) — for the treatment of relapsed/refractory plasma cell neoplasms were formally presented at the 2026 International Myeloma Society (IMS) Annual Meeting, and reported by Professor Jin Lu of Peking University People's Hospital as an oral presentation at the meeting (Abstract
More news about: IASO Bio
Sep 26, 2026, 23:03 ET 2026 IMS | IASO Bio Presented First-in-Human Data of BCMA-Targeted In Vivo CAR-T Cell Therapy IASO206
for IASO206, its internally developed BCMA-targeted in vivo CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (R/R MM) at the 2026 International Myeloma Society (IMS) Annual Meeting. IASO206 is designed to generate functional BCMA-directed CAR-T cells directly in patients
More news about: IASO Bio
Sep 25, 2026, 11:32 ET 2026 IMS | IASO Bio Presents First-in-Human Phase 1 Data of RD140, a Fully Human BCMA/GPRC5D Dual-Targeted FasT CAR-T
based on the FasT CAR-T rapid manufacturing platform — at the 2026 International Myeloma Society (IMS) Annual Meeting. The study is an investigator-initiated trial (IIT) in patients with relapsed/refractory multiple myeloma (R/R MM) and plasma cell leukemia (PCL), designed to evaluate the safety, tolerability,
More news about: IASO Bio
Sep 25, 2026, 10:54 ET 2026 IMS | Updated FUMANBA-1 Analysis of IASO Bio's FUCASO Reveals That In Vivo Durable Persistence of CAR-T cells Is Associated with Sustained MRD Negativity and Delayed Disease Progression
product, FUCASO (equecabtagene autoleucel injection, Eque-cel) — were presented as a poster at the 2026 International Myeloma Society (IMS) Annual Meeting[1] (Abstract No.: PA-469). The results showed that durable persistence of FUCASO
More news about: IASO Bio
Sep 25, 2026, 07:00 ET Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myeloma
medical congresses, including the International Myeloma Society (IMS) Annual Meeting, and contribute to the growing body of evidence supporting earlier use of CARVYKTI® in multiple myeloma.About multiple myeloma Multiple myeloma is a complex blood cancer that affects a type
More news about: Johnson & Johnson
Sep 24, 2026, 09:00 ET Verana Health Introduces New AI Agents to Expedite and Streamline R&D
minutes instead of weeks, complete with SQL output ready for data scientist validation.For example, a researcher assessing therapies for multiple myeloma may want to run numerous queries:"How many patients received at least one line of therapy?""Of these patients, how
More news about: Verana Health
Sep 23, 2026, 09:46 ET New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myeloma
teclistamab as a combination regimen.About multiple myelomaMultiple myeloma is a complex blood cancer that affects a type of white blood cell called plasma cells, which are found in the bone marrow.4 In multiple myeloma, these plasma cells proliferate and spread rapidly and replace
More news about: Johnson & Johnson
Sep 22, 2026, 08:00 ET Cizzle Bio Champions Early Cancer Detection as Sponsor of Prevent Cancer Foundation's 32nd Annual Gala
family members of patients who benefited from cancer research and clinical trials; Gerry McDougall, national patient advocate, chairman of the Multiple Myeloma Research Foundation and long-standing board member of Conquer Cancer, the ASCO Foundation; and Luke Blanchat, government relations director at Checkmate
More news about: Cizzle Bio
Sep 20, 2026, 20:30 ET Antengene Announces First Patient Dosed in Pivotal Phase III CLINCH-3 Study of ATG-022
system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102 for acute myeloid leukemia and chronic myelomonocytic leukemia) and FLT3 x CD3 (ATG-107 for acute myeloid leukemia).To
More news about: Antengene Corporation Limited
Sep 18, 2026, 11:00 ET NAVER D2SF Invests in AI-Driven Precision Medicine Company ImpriMed
partnerships with major U.S. hospitals as it builds its human health presence in North America. In South Korea, ImpriMed has developed software for multiple myeloma prognosis and therapy-response predictions. The software has been designated an Innovative Medical Device by the Ministry of Food and Drug Safety (MFDS)
More news about: NAVER D2SF
Sep 18, 2026, 07:52 ET 2026 Tang Prize Award Ceremony Honors Six Laureates
of laboratories around the world are exploring the potential of CAR T cells. Following their success in certain leukemias and lymphomas, multiple myeloma became the next cancer to be successfully treated with CAR T cells, which are now also showing promise in rheumatology and other fields. Sadelain expressed
More news about: The Tang Prize Foundation
Sep 17, 2026, 08:30 ET AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting
objective response rate (ORR) and progression-free survival (PFS) in relapsed/refractory multiple myeloma (RRMM)Additional presentations highlight research across the breadth of AbbVie's multiple myeloma portfolio, including ABBV-2001 (ISB 2001), a trispecific T-cell engager and surzetoclax, a
More news about: AbbVie
Sep 16, 2026, 15:07 ET Medisights Pioneers New Standard: AI Agents Capture Unprecedented Near Real-Time Market Intelligence in Complex Diseases Like Multiple Myeloma
demonstrating that purpose-built Artificial Intelligence (AI) agents can seamlessly navigate the intricate, rapidly evolving landscape of Multiple Myeloma to capture actionable market intelligence at scale. By successfully training AI to track this highly complicated disease state, Medisights has pioneered
More news about: MediSights, Inc
Sep 16, 2026, 14:18 ET Medisights Pioneers New Standard: AI Agents Capture Unprecedented Near Real-Time Market Intelligence in Complex Diseases Like Multiple Myeloma
demonstrating that purpose-built Artificial Intelligence (AI) agents can seamlessly navigate the intricate, rapidly evolving landscape of Multiple Myeloma to capture actionable market intelligence at scale. By successfully training AI to track this highly complicated disease state, Medisights has pioneered
More news about: MediSights, Inc
Sep 16, 2026, 05:47 ET IASO Bio's CD20-Targeted In Vivo CAR-T Therapy IASO208 Receives FDA IND Clearance
Equecabtagene Autoleucel Injection. This CAR-T cell therapy has been approved for marketing in China for the treatment of relapsed/refractory multiple myeloma (r/r MM) in patients who have progressed after at least three prior lines of therapy. The Company is also developing this product for earlier lines
More news about: IASO Bio
Sep 15, 2026, 13:27 ET /C O R R E C T I O N -- The Galien Foundation/
Voices of LUMultiple Myeloma Research Foundation (MMRF)Path to a Cure
More news about: The Galien Foundation
Sep 14, 2026, 10:31 ET Bispecifics Market to Gain Momentum During the Forecast Period (2026-2036) with Expanding Pipeline and Increasing Therapeutic Adoption | DelveInsight
(DLBCL), Follicular Lymphoma, Multiple Myeloma, Non-small-cell Lung Cancer (NSCLC), Small-cell Lung Cancer (SCLC), Biliary Tract Cancer (BTC), Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), and others.The total incident cases of multiple myeloma in the 7MM comprised approximately
More news about: DelveInsight Business Research, LLP
Sep 14, 2026, 00:30 ET Zydus Spine Surgeons Push the Boundaries of Complex Spine Care, Delivering Excellent Outcomes Across All Ages
countries for OPDs, recalls one such case of a 65-year-old patient and his family who consulted with his team. "He had been diagnosed with multiple myeloma that put severe pressure on his spinal cord". Doctors in his home country told him surgery wasn't possible; however, after the online consultation,
More news about: Zydus Hospitals and Healthcare Research Private Limited
Sep 14, 2026, 00:26 ET Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy
a preclinical research paper evaluating the combination of ATG-037 (CD73 Small Molecule Inhibitor) and selinexor for the treatment of multiple myeloma (MM), conducted in collaboration with the Department of Hematology at Peking University Third Hospital, has been published in Cancer Gene
More news about: Antengene Corporation Limited
Sep 10, 2026, 07:00 ET BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)
Company's first approved product, APHEXDA® (motixafortide), is indicated in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is being commercialized by Ayrmid Ltd. (globally, except Asia) and Auspex Biosciences (in Asia). BioLineRx has retained the rights to develop
More news about: BioLineRx Ltd.; Hemispherian AS
Sep 09, 2026, 10:31 ET Waldenström Macroglobulinemia Market to Gain Momentum During the Forecast Period (2026-2036) Due to Launch of Novel Drug Classes Including BTK Degraders, Non-covalent BTKi, BCL-2 Inhibitors, and Targeted Radiotherapeutics | DelveInsight
Multiple Myeloma MarketMultiple Myeloma Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical
More news about: DelveInsight Business Research, LLP
Sep 04, 2026, 08:30 ET Alexandria Real Estate Equities, Inc. Highlights Its Role in Advancing Blood Cancer Innovation by Enabling Life-Changing Tenant R&D, Mission-Critical Philanthropic Initiatives and Strategic Investments
blood-forming tissue, such as bone marrow, or in cells of the immune system. There are over 100 types of blood cancers, including leukemia, lymphoma and myeloma.
More news about: Alexandria Real Estate Equities, Inc.
Sep 03, 2026, 09:15 ET AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma
Relapsed or Refractory Multiple Myeloma (RRMM)." Abstract presented at International Myeloma Society Annual Meeting, 2026. Glasgow, Scotland.Hej-Ali S, Banwell K, Mohamed H, et al. Toxicities of CAR-T, bispecific antibodies, and antibody-drug conjugates in multiple myeloma: a practical approach to risk
More news about: AbbVie
Sep 01, 2026, 16:05 ET Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is
More news about: Karyopharm Therapeutics Inc.